Source: Annual Congress 2007 - Treatment of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Bukreeva, S. Nesterovich, O. Akbasheva, G. Seitova, T. Melnik, E. Dementieva (Tomsk, Russian Federation). Anti-inflammatory activity of Erespal (Fenspirid, Servie, France) in COPD patients. Eur Respir J 2007; 30: Suppl. 51, 592

Member's Comments

No comment yet.

Related content which might interest you: Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015 Is hyaluronic acid (HA) a marker of effectiveness of anti-inflammatory therapy in COPD patients? Source: Annual Congress 2013 –COPD: markers and inflammation Year: 2013 Effect of short-acting bronchodilators (BDs) on the severity of respiratory muscle (RM) strength in COPD patients (pts) Source: Annual Congress 2013 –COPD treatment Year: 2013 Changes in drug prescription for asthma (A) and COPD (C) by GPs in Italy Source: Annual Congress 2010 - Pharmacological treatment in primary care Year: 2010 Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Are we missing asthma COPD overlap (ACO) diagnosis among patient with COPD?Alameeri Amel(1), Dudina Alexandra(1) , Stephen Lane(1), Kennedy Merian(2) Source: International Congress 2019 – FeNO in airway diseases and asthma-COPD overlap identification Year: 2019 Long term oxygen therapy (LTOT) prescription in chronic obstructive pulmonary disease (COPD) patients in Wigan (northwest England) Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 The role of proinflammatory cytokines in severe COPD patients before and after roflumilast treatment Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Influence of bacterial colonization (BC) on the level of systemic inflammatory markers (SIM) in COPD patients (pts) Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 Safety, pharmacodynamics (PD) and pharmacokinetics (PK) of darotropium (DARO) and vilanterol (VI) in healthy subjects: Two phase 1 studies Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Principles of optimization of anti-inflammatory therapy in COPD patients (pts) due to C-reactive protein (CRP) level Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Tolerability of different dosing regimens of roflumilast in severe COPD (OPTIMIZE) Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Glycopyrronium (GLY) and tiotropium (TIO) comparison: Lung function, dyspnea and health status in COPD patients in all GOLD groups Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Efficacy and tolerability of budesonide/formoterol (B/F) added to tiotropium (T) vs T alone in East-Asian patients (pts) with severe/very severe chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 The impact of antimicrobial resistance on the cost-effectiveness of empirical treatment of community-acquired pneumonia (CAP) in France (FR), Belgium (BE) and Germany (DE) Source: Annual Congress 2007 - Community-acquired pneumonia: from aetiology to complication Year: 2007 Erdosteine improves airflow in patients with severe exacerbation of COPD (AECOPD) Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016